Evidence map›Paper›PMID 35764498›Full record

ArticleBlood advances2022

Refining the migration and engraftment of short-term and long-term HSCs by enhancing homing-specific adhesion mechanisms.

Asma S Al-Amoodi, Yanyan Li, Arwa Al-Ghuneim, Hanaa Allehaibi, Ioannis Isaioglou, Luke E Esau, Dina B AbuSamra, Jasmeen S Merzaban

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Maladaptive trained immunity in viral infections.The Journal of clinical investigation · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. CD34Frontiers in cell and developmental biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Asma S Al-AmoodiLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-8970-3807
Yanyan LiLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-4866-7352
Arwa Al-GhuneimLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-1941-3302
Hanaa AllehaibiLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-3944-2733
Ioannis IsaioglouLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-0269-6887
Luke E EsauBioscience Core Laboratory, King Abdullah University of Science and Technology (KAUST), Thuwal, Kingdom of Saudi Arabia.ORCID 0000-0002-6036-7213
Dina B AbuSamraLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-0974-5362
Jasmeen S MerzabanLaboratory of Cell Migration and Signaling, Bioscience Program, Biological and Environmental Sciences and Engineering Division, and.ORCID 0000-0002-7276-2907
Bioscience (China) · CNKing Abdullah University of Science and Technology · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In contrast to the short-term (ST) CD34+ stem cells, studies have suggested that long-term (LT) hematopoietic stem cells (HSCs) found in the CD34- stem cell pool have trouble migrating and engrafting when introduced through IV. To understand why these deficiencies exist, we set out to fully elucidate the adhesion mechanisms used by ST and LT-HSCs to migrate to the bone marrow(BM). Specifically focusing on murine ST-HSCs (Flk2-CD34+) and LT-HSCs (Flk2-CD34-), we observed a distinctive expression pattern of BM homing effectors necessary for the first step, namely sialyl Lewis-X (sLex) (ligand for E-selectin), and the second step, namely CXCR4 chemokine receptor (receptor for SDF-1). sLex expression was higher on Flk2-CD34+ ST-HSCs (>60%) compared with Flk2-CD34- LT-HSCs (<10%), which correlated to binding to E-selectin. Higher concentrations of CXCR4 were observed on Flk2-CD34+ ST-HSCs compared with Flk2-CD34- LT-HSCs. Interestingly, the expression of CD26, a peptidase known to deactivate chemokines (ie, SDF-1), was higher on Flk2-CD34- LT-HSCs. Given that both E-selectin-binding and CXCR4-mediated migration are compromised in Flk2-CD34- LT-HSCs, we aimed to enhance their ability to migrate using recombinant human fucosyltransferase 6 (rhFTVI) and the CD26 inhibitor, Dip A (diprotin A). To this end, we observed that although LT-HSCs expressed low concentrations of sLex, they were able to engraft when transplanted into recipient mice. Moreover, although both CD26 inhibition and fucosylation enhanced migration of both HSC populations in vitro, only pretreatment of LT-HSCs with Dip A enhanced engraftment in vivo after transplantation into recipient mice. Remarkably, fucosylation of Flk2-CD34+ ST-HSCs consistently led to their ability to transplant secondary recipients. These data suggest that using fucosylation and Dip A to overcome the molecular disparity in adhesion mechanisms among ST-HSCs and LT-HSCs differentially influences their abilities to migrate and engraft in vivo and promotes the ability of ST-HSCs to engraft secondary recipient mice, the gold standard for testing functionality of LT-HSCs.

Indexed as

Dipeptidyl Peptidase 4E-SelectinAnimalsAntigens, CD34Bone MarrowHematopoietic Stem CellsHumansMiceAntigens, CD34Dipeptidyl Peptidase 4E-Selectin

Identifiers

PMID35764498
PMCPMC9636332
OpenAlexW4283700628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.